Medicus Pharma inks Pfizer CD228V co-development and global license deal
Medicus Pharma entered a co-development and license agreement with Pfizer for CD228V, a worldwide, early clinical-stage CD228-targeting antibody-drug conjugate. The deal grants an exclusive, sublicensable patent license and includes $12M upfront plus $1B+ milestones.